Zentrum für Angst- und Depressionsbehandlung
Zurich, 8008, Switzerland
Location status: Recruiting
NCT Number: NCT03983291
This study investigates if a physiotherapeutic exercise program designed to relax facial muscles associated with the expression of negative emotions and to activate and strengthen facial muscles associated with the expression of positive emotions can reduce the symptoms of depression and improve wellbeing and quality of life in the affected patients.
Interested in participating?
Request Info18 year–65 year
All sexes
Interventional
Not applicable
Zurich, 8008, Switzerland
Location status: Recruiting
Activity of the facial musculature expresses emotions, but also generates proprioceptive signals to the emotional brain that maintain and reinforce the expressed emotions. This has been described by Charles Darwin and William James in the facial feedback hypothesis.
Studies have shown that interruption of facial feedback by the injection of botulinum toxin into the corrugator and procerus muscles, which express negative emotions like sadness, anger, and fear, can reduce the symptoms of depression.
In the present study we investigate, if similar effects can be achieved by a relaxing massage of these and other muscles that are associated with the expression of negative emotions and if strengthening exercises of muscles that express positive emotions, the zygomaticus and orbicularis oculi muscles, can contribute to the rehabilitation of positive emotionality in depression. After instruction by a physiotherapist, participants will practice the exercises daily for 15 minutes.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Facial massage and force exercise
Time frame: 6 weeks
The Montgomery-Asberg Depression Rating Scale (MADRS) is an expert rating scale with 10 items for the measurement of the severity of depressive symptoms. Change in depression severity is measured as change in the total score of the scale (0-60 points).
Time frame: 3, 9, 12 weeks
The Montgomery-Asberg Depression Rating Scale (MADRS) is an expert rating scale with 10 items for the measurement of the severity of depressive symptoms. Change in depression severity is measured as change in the total score of the scale (0-60 points).
Time frame: 3, 6, 9, 12 weeks
The Patient-Health-Questionnaire-9 (PHQ-9) is a self-rating scale with 9 items for the measurement of the severity of depressive symptoms. Change in depression severity is measured as change in the total score of the scale (0-27 points).
Time frame: 3, 6, 9, 12 weeks
The Snaith-Hamilton-Pleasure-Scale (SHAPS-D) is a self-rating scale with 14 items for the measurement of pleasure. Change in anhedonia (inability to experience pleasure) is measured as change in the total score of the scale (0-14 points).
Contact information is provided by the study sponsor or research team.
Axel Wollmer, MD
CONTACT
Patricia Waldvogel, PhD
CONTACT
Zentrum für Angst und Depressionsbehandlung Zürich
Other
Facial Rehabilitation of Wellbeing in Depression: a Randomized Controled Trial of a Facial Physiotherapeutic Exercise Program in the Treatment of Depression
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07033052
Anxiety, Anxiety Disorders
Cleveland, Ohio, United States
View Trial DetailsNCT06713616
Behavior, Behavioral Symptoms
Milford, Connecticut, United States
View Trial DetailsNCT07413874
Addison Disease, Adrenal Gland Diseases
Boone, North Carolina, United States
View Trial DetailsNCT02543983
Behavior, Behavioral Symptoms
Bethesda, Maryland, United States
View Trial Details